跳至主要内容
临床试验/NCT02064634
NCT02064634Unknown不适用

A Multicenter, Comparative, Open Label, Prospective Observational Study on Discontinuation of Medication Due to Gastrointestinal Adverse Effects for the Patients Being Treated for Osteoarthritis With Anti-inflammatory Analgesic Drug

Green Cross Corporation1 个研究点 分布在 1 个国家目标入组 6,700 人开始时间: 2014年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
6,700
试验地点
1
主要终点
Discontinuation rate due to gastrointestinal adverse effects

研究概览

简要总结

This study investigates how gastrointestinal toxicity affects discontinuation of medication given to patients with osteoarthritis in routine clinical practice.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Minimum 20- year-old patients diagnosed with osteoarthritis
  • Within 2 weeks prior to participation, not taken anti-inflammatory analgesic drug such as the Shinbaro Capsule, Celecoxib Capsule and NSAIDs(non-steroidal anti-inflammatory drugs)
  • Written consent form voluntarity

排除标准

  • Diagnosed with disease that may affect measurement of efficacy clinically
  • Diagnosed with clinically significant phycological disorder, and taking medication
  • Participated in a clinical trial within 4 weeks
  • Pregnant or lactating woman
  • History of malignant disease within the previous 5 years
  • Patients who seem not to participate in the study at investigator's discretion

结局指标

主要结局

Discontinuation rate due to gastrointestinal adverse effects

时间窗: up to 12 weeks

次要结局

  • Rate of medication discontinuation recorded as lack of efficacy(up to 12 weeks)
  • Rate of medication discontinuation(up to 12 weeks)
  • Discontinuation rate due to adverse events(up to 12 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验